TLDR: Swiss business-to-business and life-sciences companies are giving one specialist ownership of the whole revenue process, from first contact to renewal, because buyers now judge the company on the consistency of every handoff.
Revenue operations puts marketing, sales and customer success on one process
Revenue operations (RevOps) is the discipline of running marketing, sales and customer success as one system with one set of data, one set of definitions and one owner for the process that connects them. Gartner framed the idea in May 2021, when it predicted that 75% of the highest-growth companies in the world would deploy a RevOps model by 2025. The analyst firm described progressive organisations that “align sales, marketing and customer success technology, data and KPIs”, meaning key performance indicators, to build an end-to-end view of the revenue engine, and it contrasted siloed functions with “a continuous feedback loop across the buyer journey”.
RevOps borrows its logic from software: development and operations teams once worked to opposing incentives, one rewarded for shipping and the other for stability, until the DevOps movement (short for development and operations) gave both the same metrics and the same ownership. Pupsic, the revenue-operations agency based in Morges, made that parallel the centre of its May 2026 webinar briefing on RevOps and digital marketing: marketing builds pipeline, sales converts it and service retains and expands the customer, and revenue leaks wherever one team hands work to the next. RevOps applies the DevOps remedy to that leak. The model has also moved into Swiss corporate structures: Kainjoo SA announced its acquisition of Pupsic in January 2026, describing a revenue-operations agency with more than 40 active clients across Europe and 28 professionals in distributed engineering teams, and positioning RevOps as a core offering for the European market.
In a large company, RevOps becomes a team under a chief revenue officer. In a Swiss company of 50 to 500 people, the realistic version is one senior specialist, sometimes two, who owns the customer relationship management (CRM) platform, the process map from first touch to renewal, and the reporting that tells the leadership team where revenue is gained and lost.
Buyers now notice every broken handoff between marketing, sales and service
The case for a single owner rests on how business buyers behave. A Gartner survey of 632 business-to-business (B2B) buyers, published in June 2025, found that 61% prefer an overall rep-free buying experience, 73% actively avoid suppliers who send irrelevant outreach, and 69% report inconsistencies between the information on a supplier’s website and the information its sellers provide. The mechanism behind that last figure is simple: marketing edits the website on its own release cycle, sales pitches from its own deck, and each team updates its material when its own calendar allows, so the two versions drift apart until a buyer compares them. A process owner closes that gap by putting both versions on one approval path and one source of product and pricing data.
McKinsey’s B2B Pulse research, based on nearly 4,000 decision makers across 34 sectors, reports that B2B customers use an average of ten interaction channels in their buying journey, and that more than half of respondents are likely to turn elsewhere when the omnichannel experience disappoints. Ten channels managed by three departments with three dashboards produce exactly the contradictions buyers punish, and one process owner with one data model removes their source.
| Buyer signal | Finding | Source |
|---|---|---|
| Prefer a rep-free buying experience | 61% | Gartner, 2025 |
| Avoid suppliers sending irrelevant outreach | 73% | Gartner, 2025 |
| See website and seller information conflict | 69% | Gartner, 2025 |
| Interaction channels used per buying journey | 10 | McKinsey, 2024 |
Swiss law and life-sciences rules turn customer relationship management ownership into a compliance role
In Switzerland, the person who owns the CRM also owns a set of legal obligations that marketing and sales teams tend to treat as somebody else’s concern. The totally revised Federal Act on Data Protection (FADP) entered into force on 1 September 2023, and every contact record, enrichment feed and tracking field in a CRM falls under it. Electronic mass advertising carries its own rule: under article 3 letter o of the Federal Act against Unfair Competition, the Federal Office of Communications explains that automated mass advertising by email or short message service (SMS) is allowed only if recipients have explicitly given their consent, with an exception for existing customers buying products of the same type and an easy, free-of-charge refusal option in every message. A RevOps specialist turns those rules into consent fields, suppression lists and workflow logic, so that compliance runs inside the system itself.
In life sciences, a further layer applies: advertising of prescription-only medicines to the general public is prohibited in Switzerland, as the CMS expert guide to the advertising of medicines summarises, and professional promotion must be evidence-based and kept to professional audiences. For a pharmaceutical or medical-technology company, the CRM therefore has to separate healthcare-professional audiences from the public, record which approved material reached whom, and keep promotional and medical channels apart. Edward Galle’s analysis of the roles behind omnichannel in life sciences shows how those audiences multiply once field, digital and medical teams share one customer.
Veeva Systems, whose CRM has long been the default in pharmaceutical field sales, stated in its annual report for the fiscal year ended 31 January 2025 that it plans to let its agreement with Salesforce run to expiry, that “Veeva CRM will be supported until September 1, 2030”, and that the migration of customers to Vault CRM would “require time and expense, which may be significant”. Every Swiss affiliate running Veeva CRM faces a platform decision before that date, either Vault CRM or an alternative such as Salesforce’s own life-sciences offering. A migration of that size goes far better when one person already owns the data model, the field definitions and the integrations, and it goes badly when ownership is split between a global information technology (IT) team and a local marketing manager.
The RevOps specialist owns the process, the platform, the numbers, compliance and adoption
Job descriptions for this role vary widely, so a clear scope helps both employers and candidates. Edward Galle frames the role around five responsibilities, each of which a company can test at interview, and each of which has a public example that shows what is at stake.
The revenue process. The specialist maps every stage from first contact to renewal, writes the shared definitions (what counts as a qualified lead, an opportunity, an at-risk account) and agrees the service levels for each handoff, such as how quickly sales responds to an inbound request and when customer success takes over after signature. HubSpot, which retired its own funnel model in favour of a flywheel, states the problem plainly in its explanation of that model: “Siloed work and poor handoff between teams are some of the biggest areas of friction in most flywheels”, and it gives the example that weak alignment between sales and customer success “can create unhappy customers”. Pupsic’s webinar briefing recommends a weekly 30-minute revenue stand-up in which marketing, sales and service review one slide of the previous week’s stage conversions, a simple ritual that gives the process owner a standing forum.
The CRM platform. The specialist owns the data model, permissions, integrations and data quality of HubSpot, Salesforce, Veeva or whichever platform the company runs, and decides with the business which tools enter the stack. The scale of that responsibility is visible in the Veeva migrations now under way: Veeva reported in March 2025 that at GSK “more than 15,000 users in 50+ countries are expected to be live by late 2025” on Vault CRM. Every one of those users depends on someone who owns field definitions, data transfer and integrations at country level. Ownership means accountability for duplicates, missing fields and broken automations, with the authority to fix them.
The numbers. The specialist produces one set of revenue reports that marketing, sales, finance and the executive team all accept: pipeline by stage, conversion between stages, sales cycle length, retention and expansion. Gartner’s State of Sales Operations research shows why this matters: only 45% of sales leaders and sellers have high confidence in their organisation’s forecasting accuracy, and only 47% of respondents believe their organisations have high-quality data. A single agreed figure for pipeline, built on one data model, replaces the monthly debate about whose spreadsheet is right.
Compliance by design. Consent, retention and audience rules from the FADP, the unfair-competition rules on mass advertising and, in life sciences, the advertising rules for medicines are built into fields and workflows. The Swiss data-protection authority has shown how concrete this becomes. The Federal Data Protection and Information Commissioner (FDPIC) recommended in April 2024 that Digitec Galaxus give customers an option to object to the use of their personal data for marketing; the retailer reported in November 2025 that customers can now switch behavioural personalisation on or off in their account settings, and the FDPIC closed the case in February 2026. That outcome is a CRM configuration task: a preference field, a link to the cookie layer and a change to the registration form.
Enablement. The specialist trains sales and service teams on the process and the tools, and collects their feedback to improve both. A CRM that the field force ignores produces empty fields, so adoption is part of the job. Boehringer Ingelheim’s choice of platform illustrates the weight companies put on it: Veeva reports that for the company “a key factor was avoiding disruption at all costs”, and that the choice “requires minimal retraining for field forces”. Retraining cost and field disruption sit squarely in the RevOps specialist’s remit.
Across the five areas, the specialist answers for a short list of indicators and a defined set of tools. Edward Galle’s view is that the indicators a Swiss employer should write into the role are pipeline by stage, conversion between stages, sales cycle length, speed of response to inbound requests, gross and net revenue retention and forecast accuracy, each defined once and reported from the same data model. Pupsic’s briefing makes the retention point explicit, advising companies to give a net revenue retention dashboard the same prominence as the pipeline dashboard. The tool stack the specialist governs usually has four layers: the CRM itself, marketing automation, a reporting or business intelligence (BI) layer, and the integrations that connect them to the website, the enterprise resource planning (ERP) system and, in pharma, the approved-content repository. In Edward Galle’s view, the job description should name the platforms in each layer, since a candidate who has administered the same CRM and automation tools reaches full productivity much faster.
| Area | What the specialist owns | Evidence to ask for |
|---|---|---|
| Process | Stage definitions, handoff service levels | A process map they wrote and the change it produced |
| Platform | Customer relationship management (CRM) data model, integrations, data quality | A migration or clean-up they led end to end |
| Numbers | One agreed pipeline and retention report | A dashboard the executive team used weekly |
| Compliance | Consent, opt-out and audience rules in workflows | How they applied Federal Act on Data Protection (FADP) or medicines advertising rules |
| Enablement | Training and adoption by sales and service | Adoption before and after their programme |
The strongest candidates combine systems thinking with commercial credibility
RevOps sits between technology and commerce, so the best candidates usually arrive from several career paths. Strong profiles include former CRM administrators who moved closer to the business, sales or marketing operations managers who took on reporting, consultants who implemented CRM platforms for clients, and commercial excellence specialists from pharmaceutical affiliates who already manage field-force data and segmentation. The common thread is someone who can configure a system and also hold a credible conversation with a sales director about why a stage definition must change.
Employers should expect hands-on administration of at least one major CRM, comfort with data exports, spreadsheets and ideally Structured Query Language (SQL), experience connecting marketing automation, the website and the finance system, and a working grasp of the metrics that matter to a chief financial officer, such as retention and customer acquisition cost. In regulated sectors, familiarity with consent management and with the separation of promotional and medical content becomes a decisive advantage. Edward Galle’s article on brand-tech talent in pharma and medical technology describes the adjacent hybrid profile on the marketing-technology side.
A RevOps specialist in Basel or Zurich often works with German-speaking sales teams and English-speaking global headquarters; in Romandie the field force works in French. A candidate who can run a workshop in the sales team’s own language earns adoption faster than one who relies on the global template.
Salary benchmarks for RevOps sit between the information technology market and commercial roles
Employers and candidates both ask what the role pays. Official Swiss statistics group RevOps work under broader information technology and commercial categories, so the most dependable benchmark is the nearest published series. The swissICT salary study 2025, built on 39,511 salary entries from 231 organisations, puts the median base salary at the senior level at CHF 130,060. Edward Galle’s analysis Digital Hires in Swiss Pharma Are Priced Against the Technology Market, Above the Pharma Median explains how pharmaceutical employers price digital roles against that information technology market and against the commercial pay lines of the industry.
Edward Galle’s view, from its search work for Swiss employers, is that a RevOps specialist is best priced as a senior individual contributor with cross-functional authority: closer to the information technology benchmark when the role is platform-heavy, and closer to commercial management pay when the role owns forecasting and reports to the executive team. Candidates strengthen a negotiation with evidence of scope, such as the number of users on the platform, the countries covered and the revenue reported through their dashboards.
Contract and permanent RevOps hires answer different business needs
The second question in most briefs is whether to hire on contract or on a permanent basis. Edward Galle’s view is that the answer follows the work. A defined project with an end date, such as a Veeva CRM to Vault CRM migration before the 2030 support deadline or the consolidation of two CRM instances after an acquisition, suits an experienced contractor who has delivered the same migration elsewhere. The ongoing ownership of process, numbers and adoption suits a permanent hire, because the value of the role compounds as the specialist learns the products, the field force and the leadership team.
Employers can also combine both: a contractor leads the migration while a permanent RevOps specialist joins early enough to co-own the design and inherit the platform. That sequence keeps the knowledge inside the company after the contractor leaves, and it gives the permanent hire a clear first project, which experienced candidates look for when they compare offers.
Hiring well starts with giving the role authority across all three teams
Placing RevOps inside one of the three departments it is meant to connect undermines the role from the first week. A specialist reporting to the head of marketing is quickly read by sales as a marketing resource, and the reverse holds too. The role works best reporting to the chief executive, the chief operating officer or a chief revenue officer, with a written mandate that covers process, platform and reporting across marketing, sales and customer success.
A focused selection process follows from the scorecard in Exhibit 2. A useful work sample is a two-hour exercise on an anonymised CRM export: the candidate identifies data-quality issues, proposes stage definitions and sketches the first dashboard. A second interview with the sales and customer-success leads tests whether the candidate can win their trust. The final conversation with finance confirms that the candidate’s numbers will be accepted at board level. Companies hiring before a Veeva migration or a CRM consolidation should say so in the advertisement, because experienced RevOps candidates look for a mandate with a clear first project.
For candidates, a curriculum vitae (CV) that names the platform, the size of the database, the process redesigned and the measurable change, such as a shorter sales cycle or a cleaner pipeline review, reads as RevOps experience. A CV that lists tools and stops there reads as administration.
Swiss employers that hire one RevOps owner gain a revenue engine buyers can trust
As of August 2026, Edward Galle runs RevOps Specialist search for Swiss business-to-business, pharmaceutical and medical-technology employers alongside its Brand Tech Specialist search. Employers can brief a search through the team, and RevOps and CRM professionals can submit a CV or browse current openings. Edward Galle’s overview of the digital skills commercial pharma teams need places the role within the wider commercial organisation.
This article has been reviewed by Haider Alleg, Managing Partner at Kainjoo SA.
References
- Gartner. Gartner Predicts 75% of the Highest Growth Companies in the World Will Deploy a RevOps Model by 2025. 17 May 2021. https://www.gartner.com/en/newsroom/press-releases/2021-05-17-gartner-predicts-75–of-the-highest-growth-companies-
- Pupsic / treatmybrand.com. Pupsic Webinar: Why RevOps is reshaping digital marketing? 11 May 2026. https://treatmybrand.com/pupsic-webinar-why-revops-is-reshaping-digital-marketing/
- treatmybrand.com. Kainjoo SA acquires Pupsic XYZ. 4 January 2026. https://treatmybrand.com/kainjoo-sa-acquires-pupsic-xyz/
- Gartner. Gartner Sales Survey Finds 61% of B2B Buyers Prefer a Rep-Free Buying Experience. 25 June 2025. https://www.gartner.com/en/newsroom/press-releases/2025-06-25-gartner-sales-survey-finds-61-percent-of-b2b-buyers-prefer-a-rep-free-buying-experience
- McKinsey & Company. Five fundamental truths: How B2B winners keep growing. 12 September 2024. https://www.mckinsey.com/capabilities/growth-marketing-and-sales/our-insights/five-fundamental-truths-how-b2b-winners-keep-growing
- Swiss Federal Council. 30th Annual Report 2022/2023: New law strengthens the FDPIC. 26 June 2023. https://www.admin.ch/gov/en/start/documentation/media-releases.msg-id-96037.html
- Federal Office of Communications (OFCOM). When is mass sending allowed? 2 July 2021. https://www.bakom.admin.ch/en/when-is-mass-sending-allowed
- CMS. CMS Expert Guide to Advertising of Medicines and Medical Devices: Switzerland. Updated 8 May 2024. https://cms.law/en/int/expert-guides/cms-expert-guide-to-advertising-of-medicines-and-medical-devices/switzerland
- Veeva Systems Inc. Annual Report on Form 10-K for the fiscal year ended 31 January 2025. March 2025. https://www.sec.gov/Archives/edgar/data/1393052/000139305225000022/veev-20250131.htm
- Dick, J. HubSpot. The Flywheel Model. Originally published 2018, updated 14 July 2026. https://blog.hubspot.com/marketing/our-flywheel
- Moore, C. Veeva Systems. Why We Chose Veeva Vault CRM: BioNTech, Boehringer Ingelheim, and GSK. 19 March 2025. https://www.veeva.com/blog/why-we-chose-veeva-vault-crm-biontech-boehringer-ingelheim-and-gsk/
- Gartner. Gartner Says Less Than 50% of Sales Leaders and Sellers Have High Confidence in Forecasting Accuracy. 12 February 2020. https://www.gartner.com/en/newsroom/press-releases/2020-02-12-gartner-says-less-than-50–of-sales-leaders-and-selle
- Federal Data Protection and Information Commissioner (FDPIC). Digitec Galaxus: investigation closed. 12 February 2026. https://www.edoeb.admin.ch/en/digitec-galaxus-en
- swissICT. Saläre der ICT 2025. 2 September 2025. https://www.swissict.ch/salaere-der-ict-2025/
